BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual ...
The Chinese biopharmaceutical company achieved profitability milestone in its full-year financial performance driven by drug sales growth.
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results ...
Supreme Court bars stem cell therapy for Autism Spectrum Disorder as NMC limits HSCT use to 32 approved blood cancers and ...
Revenues for year 2025 were RMB802.6 million, representing a year-over-year increase of 201.2%. Net profit for year 2025 ...
In compliance with the Supreme Court of India judgment on the use of stem cell therapy, the National Medical Commission (NMC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results